These findings suggest that targeting the expression of the IGF1R-mTOR pathway in astrocytes may represent a viable gene therapy strategy for SOD1 ALS and other potential neurodegenerative diseases of the nervous system [188]. This evidence concerns the gene MTOR and amyotrophic lateral sclerosis.